


Oslo, 5 May 2017

In  accordance with the authorisation granted  by the Annual General Meeting 19
May  2016, the Board of Directors of PCI Biotech Holding ASA has awarded a total
of  340,000 share options to key employees. Each share option gives the right to
subscribe  for or acquire one share per  option (after PCI Biotech Holding ASA's
choice),  at a strike price  of NOK 24.95, equal to  the volume weighted average
share  price (VWAP) for  the last 5 days  of trade prior  to the grant date. The
options  can be exercised with  1/3 of the options after  one year, further 1/3
after  two years  and the  last third  after three  years. The share options are
lapsing in Q3 2022.

Of  these share options, 95,000 share options  were allotted to Per Walday, CEO.
After  the allocation, Per Walday holds a total portfolio of 120,000 unexercised
share options and 63,561 shares.

60,000 share  options were allotted to Anders Høgset, CSO. After the allocation,
Anders  Høgset holds a  total portfolio of  77,000 unexercised share options and
61,375 shares.

50,000 share   options   were  allotted  to  Ronny  Skuggedal,  CFO.  After  the
allocation, Ronny Skuggedal holds a total portfolio of 116,000 unexercised share
options and 25,066 shares.

20,000 share   options  were  allotted  to  Kristin  Eivindvik,  PD.  After  the
allocation,  Kristin  Eivindvik  holds  a  total portfolio of 44,500 unexercised
share options and 16,867 shares.

15,000 share   options   were  allotted  to  Gaël  L'Hévéder,  CBDO.  After  the
allocation,  Gaël L'Hévéder holds a total portfolio of 106,000 unexercised share
options and 10,000 shares.

The  current authorisation,  as of  19 may 2016, allows  for a total of 745,000
share options, of which 735,000 now have been granted by the Board of Directors.

For more information, please contact:
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section
5 -12 of the Norwegian Securities Trading Act.


 
    